BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20470445)

  • 1. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
    Olsson A; Björk A; Vallon-Christersson J; Isaacs JT; Leanderson T
    Mol Cancer; 2010 May; 9():107. PubMed ID: 20470445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
    Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
    Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
    Dalrymple SL; Becker RE; Isaacs JT
    Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.
    Deronic A; Tahvili S; Leanderson T; Ivars F
    BMC Cancer; 2016 Jul; 16():440. PubMed ID: 27400708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
    Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
    Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors.
    Firlej V; Mathieu JR; Gilbert C; Lemonnier L; Nakhlé J; Gallou-Kabani C; Guarmit B; Morin A; Prevarskaya N; Delongchamps NB; Cabon F
    Cancer Res; 2011 Dec; 71(24):7649-58. PubMed ID: 22037878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
    Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F
    Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
    García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
    Isaacs JT; Pili R; Qian DZ; Dalrymple SL; Garrison JB; Kyprianou N; Björk A; Olsson A; Leanderson T
    Prostate; 2006 Dec; 66(16):1768-78. PubMed ID: 16955399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
    Isaacs JT; Antony L; Dalrymple SL; Brennen WN; Gerber S; Hammers H; Wissing M; Kachhap S; Luo J; Xing L; Björk P; Olsson A; Björk A; Leanderson T
    Cancer Res; 2013 Feb; 73(4):1386-99. PubMed ID: 23149916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.
    Chang CC; Lin MT; Lin BR; Jeng YM; Chen ST; Chu CY; Chen RJ; Chang KJ; Yang PC; Kuo ML
    J Natl Cancer Inst; 2006 Jul; 98(14):984-95. PubMed ID: 16849681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
    Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
    Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
    Isaacs JT; Dalrymple SL; Rosen DM; Hammers H; Olsson A; Leanderson T
    Oncotarget; 2014 Sep; 5(18):8093-106. PubMed ID: 25193858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.
    Dalrymple SL; Becker RE; Zhou H; DeWeese TL; Isaacs JT
    Prostate; 2012 May; 72(6):638-48. PubMed ID: 21837778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digoxin inhibits blood vessel density and HIF-1a expression in castration-resistant C4-2 xenograft prostate tumors.
    Gayed BA; O'Malley KJ; Pilch J; Wang Z
    Clin Transl Sci; 2012 Feb; 5(1):39-42. PubMed ID: 22376255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
    Komuro A; Yashiro M; Iwata C; Morishita Y; Johansson E; Matsumoto Y; Watanabe A; Aburatani H; Miyoshi H; Kiyono K; Shirai YT; Suzuki HI; Hirakawa K; Kano MR; Miyazono K
    J Natl Cancer Inst; 2009 Apr; 101(8):592-604. PubMed ID: 19351925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia.
    Huang S; Guo Y; Jacobi A; Li Z; Huang S; He J; Liu X; Tang Y
    Cell Physiol Biochem; 2016; 39(2):709-20. PubMed ID: 27448695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma.
    Veliceasa D; Ivanovic M; Hoepfner FT; Thumbikat P; Volpert OV; Smith ND
    FEBS J; 2007 Dec; 274(24):6365-77. PubMed ID: 18021253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions.
    Chae KS; Kang MJ; Lee JH; Ryu BK; Lee MG; Her NG; Ha TK; Han J; Kim YK; Chi SG
    Oncogene; 2011 Mar; 30(10):1213-28. PubMed ID: 21057546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.